Cargando…
Lysine Acetyltransferase Inhibitors From Natural Sources
Acetylation of histone and non-histone protein lysine residues has been widely described as a critical modulator of several cell functions in humans. Lysine acetyltransferases (KATs) catalyse the transfer of acetyl groups on substrate proteins and are involved in multiple physiological processes suc...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434864/ https://www.ncbi.nlm.nih.gov/pubmed/32903408 http://dx.doi.org/10.3389/fphar.2020.01243 |
_version_ | 1783572225573519360 |
---|---|
author | Fiorentino, Francesco Mai, Antonello Rotili, Dante |
author_facet | Fiorentino, Francesco Mai, Antonello Rotili, Dante |
author_sort | Fiorentino, Francesco |
collection | PubMed |
description | Acetylation of histone and non-histone protein lysine residues has been widely described as a critical modulator of several cell functions in humans. Lysine acetyltransferases (KATs) catalyse the transfer of acetyl groups on substrate proteins and are involved in multiple physiological processes such as cell signalling, metabolism, gene regulation, and apoptosis. Given the pivotal role of acetylation, the alteration of KATs enzymatic activity has been clearly linked to various cellular dysfunctions leading to several inflammatory, metabolic, neurological, and cancer diseases. Hence, the use KAT inhibitors (KATi) has been suggested as a potentially successful strategy to reverse or prevent these conditions. To date, only a few KATi have proven to be potential drug candidates, and there is still a keen interest in designing molecules showing drug-like properties from both pharmacodynamics and pharmacokinetics point of view. Increasing literature evidence has been highlighting natural compounds as a wide source of molecular scaffolds for developing therapeutic agents, including KATi. In fact, several polyphenols, catechins, quinones, and peptides obtained from natural sources (including nuts, oils, root extracts, and fungi metabolites) have been described as promising KATi. Here we summarize the features of this class of compounds, describing their modes of action, structure-activity relationships and (semi)-synthetic derivatives, with the aim of assisting the development of novel more potent, isoform selective and drug-like KATi. |
format | Online Article Text |
id | pubmed-7434864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74348642020-09-03 Lysine Acetyltransferase Inhibitors From Natural Sources Fiorentino, Francesco Mai, Antonello Rotili, Dante Front Pharmacol Pharmacology Acetylation of histone and non-histone protein lysine residues has been widely described as a critical modulator of several cell functions in humans. Lysine acetyltransferases (KATs) catalyse the transfer of acetyl groups on substrate proteins and are involved in multiple physiological processes such as cell signalling, metabolism, gene regulation, and apoptosis. Given the pivotal role of acetylation, the alteration of KATs enzymatic activity has been clearly linked to various cellular dysfunctions leading to several inflammatory, metabolic, neurological, and cancer diseases. Hence, the use KAT inhibitors (KATi) has been suggested as a potentially successful strategy to reverse or prevent these conditions. To date, only a few KATi have proven to be potential drug candidates, and there is still a keen interest in designing molecules showing drug-like properties from both pharmacodynamics and pharmacokinetics point of view. Increasing literature evidence has been highlighting natural compounds as a wide source of molecular scaffolds for developing therapeutic agents, including KATi. In fact, several polyphenols, catechins, quinones, and peptides obtained from natural sources (including nuts, oils, root extracts, and fungi metabolites) have been described as promising KATi. Here we summarize the features of this class of compounds, describing their modes of action, structure-activity relationships and (semi)-synthetic derivatives, with the aim of assisting the development of novel more potent, isoform selective and drug-like KATi. Frontiers Media S.A. 2020-08-12 /pmc/articles/PMC7434864/ /pubmed/32903408 http://dx.doi.org/10.3389/fphar.2020.01243 Text en Copyright © 2020 Fiorentino, Mai and Rotili http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Fiorentino, Francesco Mai, Antonello Rotili, Dante Lysine Acetyltransferase Inhibitors From Natural Sources |
title | Lysine Acetyltransferase Inhibitors From Natural Sources |
title_full | Lysine Acetyltransferase Inhibitors From Natural Sources |
title_fullStr | Lysine Acetyltransferase Inhibitors From Natural Sources |
title_full_unstemmed | Lysine Acetyltransferase Inhibitors From Natural Sources |
title_short | Lysine Acetyltransferase Inhibitors From Natural Sources |
title_sort | lysine acetyltransferase inhibitors from natural sources |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434864/ https://www.ncbi.nlm.nih.gov/pubmed/32903408 http://dx.doi.org/10.3389/fphar.2020.01243 |
work_keys_str_mv | AT fiorentinofrancesco lysineacetyltransferaseinhibitorsfromnaturalsources AT maiantonello lysineacetyltransferaseinhibitorsfromnaturalsources AT rotilidante lysineacetyltransferaseinhibitorsfromnaturalsources |